Market Closed - Nasdaq 04:30:00 2024-04-17 pm EDT 5-day change 1st Jan Change
1.97 USD +5.35% Intraday chart for PAVmed Inc. -4.83% -52.18%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024
PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
PAVmed Inc. Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX CI
Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies CI
Transcript : PAVmed Inc., Q3 2023 Earnings Call, Nov 15, 2023
PAVmed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Pavmed Inc. Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Pre Cancer Detection CI
Transcript : PAVmed Inc., Q2 2023 Earnings Call, Aug 16, 2023
North American Morning Briefing : Stock Futures -2- DJ
PAVmed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
PAVmed Secures Extension to Regain Compliance With Nasdaq Listing Rules MT
PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell Microcap Growth Index CI
PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell Microcap Index CI
PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell 3000E Growth Index CI
PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell 3000E Index CI
Transcript : PAVmed Inc. - Shareholder/Analyst Call
Transcript : PAVmed Inc., Q1 2023 Earnings Call, May 17, 2023
North American Morning Briefing : Debt-Ceiling -2- DJ
PAVmed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : PAVmed Inc. - Shareholder/Analyst Call
Transcript : PAVmed Inc., Q4 2022 Earnings Call, Mar 15, 2023
PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
PAVmed Inc. announced that it expects to receive $11.11111 million in funding from Lucid Diagnostics Inc. and others CI
PAVmed Inc. announced that it has received $13.625 million in funding CI
Chart PAVmed Inc.
More charts
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.97 USD
Average target price
15.38 USD
Spread / Average Target
+680.46%
Consensus
  1. Stock Market
  2. Equities
  3. PAVM Stock
  4. News PAVmed Inc.
  5. PAVmed : Unveils New Digital Health Subsidiary